Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.37 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.37 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.37 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164106 | 0.88 | DPP4 (0.42) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL19734489 | 0.88 | DPP4 (0.42) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL19734488 | 0.88 | DPP4 (0.42) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL18249632 | 0.88 | DPP4 (0.47) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL20164090 | 0.87 | DPP4 (0.45) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL18249604 | 0.87 | DPP4 (0.44) | DPP4USP30GPR119KDM4EMAPT | |
| SCHEMBL19713392 | 0.87 | DPP4 (0.40) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL19713262 | 0.84 | DPP4 (0.43) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL18249625 | 0.84 | DPP4 (0.42) | DPP4USP30MAP3K14GPR119PDE4B | |
| SCHEMBL23211978 | 0.83 | HDAC1 (0.46) | DPP4USP30GPR119PDE4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107646031-B | Azetidine derivatives as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3297987-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2019-05-15 | — | — | EP | disclosed |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-01-31 | — | — | US | disclosed |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES (SE) | 2018-10-02 | — | — | US | disclosed |
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | US | disclosed |
| EP-3297987-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185032-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC18A1, SLC18A3 | DPP4 4657/4885USP30 2586/4885MAP3K14 1152/4885 |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A3 | DPP4 4230/4885USP30 2001/4885MAP3K14 1297/4885 |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A1 | DPP4 4544/4885USP30 2513/4885MAP3K14 1211/4885 |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC6A2, SLC18A3 | DPP4 4238/4885USP30 1969/4885MAP3K14 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.